190 related articles for article (PubMed ID: 28959506)
1. Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases.
Nguyen SM; Castrellon A; Vaidis O; Johnson AE
Cureus; 2017 Jul; 9(7):e1511. PubMed ID: 28959506
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases.
Patel KR; Shoukat S; Oliver DE; Chowdhary M; Rizzo M; Lawson DH; Khosa F; Liu Y; Khan MK
Am J Clin Oncol; 2017 Oct; 40(5):444-450. PubMed ID: 26017484
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis.
Bodensohn R; Werner S; Reis J; Pazos Escudero M; Kaempfel AL; Hadi I; Forbrig R; Manapov F; Corradini S; Belka C; Theurich S; Heinzerling L; Schlaak M; Niyazi M
Clin Transl Radiat Oncol; 2023 Mar; 39():100573. PubMed ID: 36655118
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
6. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
[TBL] [Abstract][Full Text] [Related]
7. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
8. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.
Patil CG; Pricola K; Sarmiento JM; Garg SK; Bryant A; Black KL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD006121. PubMed ID: 28945270
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
Jablonska PA; Muniz T; Ribeiro M; Liu ZA; Ye XY; Devaraja K; Laperriere N; Millar BA; Conrad T; Kongkham P; Butler M; Shultz DB
J Neurooncol; 2023 Aug; 164(1):199-209. PubMed ID: 37552363
[TBL] [Abstract][Full Text] [Related]
10. SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases.
Khan M; Lin J; Liao G; Tian Y; Liang Y; Li R; Liu M; Yuan Y
Technol Cancer Res Treat; 2018 Jan; 17():1533033818798792. PubMed ID: 30213236
[TBL] [Abstract][Full Text] [Related]
11. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.
An Y; Jiang W; Kim BYS; Qian JM; Tang C; Fang P; Logan J; D'Souza NM; Haydu LE; Wang XA; Hess KR; Kluger H; Glitza IC; Mahajan A; Welsh JW; Lin SH; Yu JB; Davies MA; Hwu P; Sulman EP; Brown PD; Chiang VLS; Li J
Radiother Oncol; 2017 Oct; 125(1):80-88. PubMed ID: 28916225
[TBL] [Abstract][Full Text] [Related]
14. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
15. Which is the best treatment for melanoma brain metastases? A Bayesian network meta-analysis and systematic review.
Li C; Li K; Zhong S; Tang M; Shi X; Bao Y
Crit Rev Oncol Hematol; 2024 Feb; 194():104227. PubMed ID: 38220124
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
Dohm AE; Nakashima JY; Kalagotla H; Jiang SX; Tang JD; Bhandari M; Kim Y; Graham JA; Khushalani NI; Forsyth PA; Etame AB; Liu JK; Tran ND; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Ahmed KA
Eur J Cancer; 2023 Oct; 192():113287. PubMed ID: 37657227
[TBL] [Abstract][Full Text] [Related]
17. Comparison of WBRT alone, SRS alone, and their combination in the treatment of one or more brain metastases: Review and meta-analysis.
Khan M; Lin J; Liao G; Li R; Wang B; Xie G; Zheng J; Yuan Y
Tumour Biol; 2017 Jul; 39(7):1010428317702903. PubMed ID: 28675121
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis.
Khan M; Zheng T; Zhao Z; Arooj S; Liao G
Front Oncol; 2020; 10():586029. PubMed ID: 33692938
[TBL] [Abstract][Full Text] [Related]
19. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
20. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]